Loratadine and desethoxylcarbonyl‐loratadine inhibit the immunological release of mediators from human FcɛRI+cells
Authors:
- V. PatellaVPV. Patella
- G. DE CrescenzoGCG. DE Crescenzo
- A. DE PaulisAPA. DE Paulis
- 1 May 1997
- journal article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 27 (5) , 559-567
Abstract
Summary: BackgroundLoratadine, a novel histamine H1‐receptor antagonist, is effective in the treatment of patients with seasonal and perennial rhinitis and some allergic skin disorders. Histamine and other chemical mediators are synthesized and immunologically released by human peripheral blood basophils and tissue mast cells (FcɛRI+cells).ObjectiveTo evaluate the effects of loratadine and its main metabolite, desethoxylcarbonyl‐loratadine (des‐loratadine), on the immunological release of preformed (histamine and tryptase) andde novosynthesized mediators (leukotriene C4: LTC4and prostaglandin D2: PGD2) from human FcɛRI+cells.MethodsHuman FcɛRI+cells purified from peripheral blood and from skin (HSMC) and lung tissue (HLMC) were preincubated with loratadine and des‐loratadine before immunological challenge with Der p 1 antigen or anti‐FcɛRI. The release of preformed mediators (histamine and tryptase) andde novosynthesized eicosanoids was evaluated in the supernatants of human FcRI+cells.ResultsPreincubation (15m in, 37°C) of purified (36–74%) basophils with loratadine (3 × 10–6–10–4M) and des‐loratadine before Der p 1 antigen or anti‐FcɛRI challenge concentration‐dependency (5–40%) inhibited the release of histamine and LTC4. Loratadine (3 × 10–6–l0–4M) and des‐loratadine also inhibited (10–40%) histamine, LTC4, and PGD2release from purified HLMC (16–68%) activated by anti‐FcɛRI. Loratadine (3 × 10–6–10–4M) and des‐loratadine caused concentration‐dependent inhibition (10–40%) of histamine, tryptase. LTC4, and PGD2release from purified HSMC (24– 72%) immunologically challenged with anti‐FcɛRI.ConclusionThese results indicate that loratadine and its main metabolite have anti‐ inflammatory activity by inhibiting the release of preformed andde novosynthesized mediators from human FcɛRI+cells.Keywords
This publication has 46 references indexed in Scilit:
- In vitro effects of H1‐antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skinAllergy, 1994
- Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadineJournal of Allergy and Clinical Immunology, 1994
- Inhibitory Effect of the H1 Antagonist Loratadine on Histamine Release from Human BasophilsInternational Archives of Allergy and Immunology, 1994
- Antihistamines in asthmaJournal of Allergy and Clinical Immunology, 1989
- Antiallergic activity of H1-receptor antagonists assessed by nasal challengeJournal of Allergy and Clinical Immunology, 1988
- Efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticariaJournal of the American Academy of Dermatology, 1988
- Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 1988
- Pharmacokinetics and Dose Proportionality of LoratadineThe Journal of Clinical Pharmacology, 1987
- Inhibition of histamine release from human basophils in vitro by calmodulin antagonistsClinical Immunology and Immunopathology, 1983
- Antihistamines in Bronchial AsthmaBMJ, 1949